Corteria Pharmaceuticals

Corteria

This biopharmaceutical company develops therapeutic drugs for patients with obesity and heart failure subpopulations.

Cardurion Pharmaceuticals

This clinical-stage biotechnology company develops therapeutic drugs for patients with heart failure and other cardiovascular diseases.

Corvidia Therapeutics

This clinical-stage biotechnology company develops precision therapies for patients with chronic kidney disease who are at high risk of cardiovascular events.

Corxel

This biopharmaceutical company develops therapies for patients with cardiometabolic diseases, including obesity, type 2 diabetes, and acute ischaemic stroke.

Estuary Biotherapeutics

This biotechnology company develops targeted genetic medicines for patients with serious kidney conditions, specifically autosomal dominant polycystic kidney disease.

Marea Therapeutics

This biotechnology company develops medicines for cardiometabolic and cardioendocrine diseases using human genetic data for patients with unmet medical needs.

AnaCardio

This biopharmaceutical company develops oral small-molecule drugs to improve cardiac contractility in patients with heart failure.

Cardior Pharmaceuticals

This biopharmaceutical company develops RNA-based therapeutics to prevent and repair heart disease for patients with conditions such as heart failure and myocardial infarction.